Facial Fat

So everything comes down to genetics? The redness shows strongest about an inch above the jawline and fades upward. It is faint near the eyes. What does that suggest?

Genetics decide it completely. Claims about melting fat in one spot are false. Only surgery can target specific areas.

The redness could be rosacea. Temperature swings, hot water, exercise heart rate, and many cosmetic ingredients trigger it. It often runs in families with English, Irish, or Scottish ancestry.

My shoulders are not very red but the skin there is patchy and slightly rough. People have asked if I had a rash, yet the condition has lasted about five years. The cheek flush becomes strongest right after running, basketball, or lifting in cold air.

That description matches rosacea, and cold is also a known trigger.

I may not respond strongly to retatrutide. After 0.9 mg two days ago and another 0.5 mg the next night I felt normal the following morning. It might take weeks to notice effects, so should I continue weekly 1.5 mg doses? The redness remains without obvious swelling. I now wonder if it is simply bloat from alcohol or carbs rather than fluid buildup.

That approach prevents reaching steady state. Retatrutide needs four to five half-lives, roughly 24 to 30 days of consistent weekly dosing, before levels stabilize. Smaller frequent injections interfere with that plateau.

Graphs comparing once-weekly versus every-three-days dosing show less variation in circulating levels with the more frequent schedule. I currently follow the split approach.

Links to the two dosing versions are available on the plotter site so the graphs can be viewed directly.

Reference to the published protocol document.

Is there any way to prevent the drawn facial look that comes with rapid loss, whether on tirzepatide or retatrutide?

The term micro-dosing is being used differently. Splitting a normal weekly total into smaller shots still counts as standard dosing and can reduce side effects while keeping steadier levels.

Definitions vary, yet splitting the weekly amount maintains more consistent circulating levels and fewer side effects than a single large dose.

When I pinch the right cheek there is a slightly tender squishy spot inside, while the left side feels only mildly squishy without tenderness.

Rapid loss from bypass, extended fasting, or GLP-1 drugs all produce facial changes. Single-agonist GLP-1s may bias the body toward greater lean-mass loss on very low calories compared with methods that raise growth hormone. Multi-agonists or higher protein intake might lessen that effect.

Current studies indicate the facial changes result from any rapid weight loss combined with slow elastin turnover rather than a unique drug mechanism. Evidence does not show GLP-1 agonists preferentially catabolize facial fat over other stores.

The first paper cited focuses on counseling patients about appearance changes rather than comparing loss methods. It does not claim GLP-1 drugs cause more facial thinning than other rapid-loss approaches.

Lymphatic drainage, gua sha, and face yoga can help if fluid is trapped. Free video demonstrations are available online.

I am in the same situation.

The papers state there is no evidence that GLP-1 agonists cause selective facial fat loss beyond what any rapid reduction produces. The effect is tied to speed of loss plus slow elastin turnover.

The statements mainly note an absence of evidence rather than proof that rates are identical across methods. Direct comparisons of facial outcomes between gastric bypass, fasting, and different GLP-1 agonists would be needed to settle the question.

Cheeks are often not perfectly symmetrical.

Quantifying ozempic face is subjective. Genetics already explain why some people lose facial fat early while others retain it longest, independent of the weight-loss method. The same pattern holds for loose skin.

We agree genetics set the order of fat loss. Ozempic face appears to involve more than simple order, including temporary loose skin and altered facial proportions after rapid reduction. A friend who lost heavily on liraglutide showed oddly proportioned features for a while.

Surgeons citing greater lean-mass loss with GLP-1s should reference supporting studies. Lecture series from research institutions present data comparing lean-mass outcomes across several weight-loss interventions and treat the findings as established.